Jitendra Kanodia
Vice President & Head of Translational Xencor
Dr. Jitendra Kanodia is the Head of Translational at Xencor that includes Clinical Pharmacology, Biomarker and Data Science functions. He obtained his Ph.D. in Chemical and Biological Engineering from Princeton University where he gained his training as a quantitative systems pharmacologist (QSP). Subsequently Jitendra worked at Merrimack Pharmaceuticals and Genentech as QSP modeler and preclinical PK lead followed by roles in Clinical Pharmacology and Project Team Leader at Theravance Biopharma before joining Xencor. Jitendra serves on the Board of Director and Clinical Pharmacology Leadership Group as a representative of Xencor at the IQ Consortium.
Dr. Kanodia is passionate about utilizing modern quantitative methodologies to accelerate drug development and getting safe therapies available to as many patients in the world as possible. Most recently, he is deeply involved in figuring out how to utilize AI to overcome the limitations of prior pharmacometric/QSP approaches or AI to inform clinical design like endpoints. He is specifically working on understanding and optimizing the clinical impact of anti-TL1A based monospecific or bispecific antibodies to improve clinical outcomes as well as patient experiences through minimization of AEs and optimization of patient reported outcomes
Seminars
- Mechanistic advantages of long-acting anti-TL1A antibodies, including optimized stability, half-life, route of administration and tissue targeting to potentially enhance efficacy and durability
- Early-stage bispecific TL1A antibodies in preclinical development, designed to address multiple disease pathways simultaneously
- Translational strategies for integrating precision medicine approaches in IBD, laying the groundwork for future patient-stratified therapy
